WanJie TianYuan Secures Nearly RMB 1 Billion in Series B Funding with MaiLin Capital as Exclusive Financial Advisor

Recently, Beijing Wanjie Medical Device Co., Ltd. (hereinafter referred to as "Wanjie Medical") announced the successful completion of a nearly 100-million-yuan B-round financing.This round of financing was led byCAS InvestmentFunds under its umbrella invest,Pulse Forest CapitalServe as the exclusive financial advisor.The funds will be mainly used for research and development in the fields of minimally invasive orthopedics and tissue regeneration, accelerating product commercialization, and the iterative development of mature products.

Since its establishment, Wanjie Medical has won the continuous favor and support of several professional investment institutions, such as Yilian Capital, with its excellent technical strength and development potential, steadily moving forward under the impetus of capital.Founder of Wanjie Medical, Ms. Zhang MeiIn response, they stated, "We would like to thank VCBeat for their assistance during this round of financing. In the current highly uncertain capital market environment, VCBeat has helped Wanjie Medical successfully complete this round of financing, providing comprehensive support to the company in many aspects such as capital planning, government relations, and key customers. We wish VCBeat continued success!"

It is reported that Wanjie Medical was founded in 2006.It is a high-tech enterprise integrating research and development, production, sales, and foreign trade.Headquartered in the Zhongguan Village Medical Device Park, known as the "Pharmaceutical Valley of China."In the development process, Wanjie MedicalSuccessElected as the Vice Chairman Unit of the China Sports Medicine Industry-University-Research Innovation Alliance, approved for a postdoctoral research workstation, and recognized as a Beijing "Specialized, Refined, Unique, and Innovative" Little Giant Enterprise, a Beijing Patent Pilot Unit, and one of the top 20 enterprises in comprehensive R&D strength in China's medical device industry, among others.Recognition from all sectors of the industry。

Wanjie Medical is committed to becoming a leading enterprise in the field of orthopedic minimally invasive and tissue regeneration.Focus on minimally invasive orthopedics (sports medicine, minimally invasive spine, joint surgery), tissue repair and regeneration, and medical aesthetics., covering a variety of products in emerging orthopedic fields such as 4K medical endoscopic camera systems, arthroscopes, percutaneous endoscopic discectomy systems, plasma surgical equipment, medical pulse lavage suction systems, meniscus suture systems, adjustable titanium plate systems with loops, suture anchors, platelet-rich plasma preparation kits, and medical bone cement. The comprehensive product portfolio has gained recognition from numerous clinical doctors.

As of now, Wanjie Medical has applied for more than 60 patents of various kinds and obtained 46 medical device registration certificates. Its core products have achieved full coverage in 32 provinces across China, with over 2,000 supply partners and access to more than 2,200 hospitals, including a coverage rate of over 80% in Class III-A hospitals. It has also established scientific research cooperation relationships with Peking University Third Hospital, PLA General Hospital, Shanghai Sixth People's Hospital, and others.

In the context of China's comprehensive national organization of medical device procurement, Wanjie Medical continues to forge ahead with an unyielding spirit, embracing no limits and fearing no challenges. It adheres to research and innovation as its core driving force, engaging in deep collaboration with numerous domestic R&D institutions, medical organizations, and renowned experts. By bringing together professional talents from various fields and relying on advanced production systems, it has builtWanjie Medical's UniqueIndustry-Academia-Research-Medicine Innovation System. And with the help of the industry-academia-research-medicine cooperation platform, keep abreast of the industry in real timeDevelopmentalInnovative direction, promoting the transformation and implementation of scientific and technological achievements,Accelerate the upgrading and iteration of products,Continuously launch medical consumables, equipment, and tools with technological leadership, allowing domestically produced medical devices to benefit more patients.

In the journey of medical device research and development innovation,Wanjie Medical's self-developed "Artificial Ligament" and "Articular Cartilage Repair Scaffold" projects have passed through the special review channel for innovative medical devices. Among them, the Articular Cartilage Repair Scaffold also won the "China Invention Patent Gold Award" issued by the World Intellectual Property Organization in 2021, filling the gap in the domestic cartilage repair field.Not only that, but the "Bioactive Glass Artificial Bone" project has also been selected for the MIIT's Biomedical Materials Innovation Task List, contributing to China's efforts in biomedical materials technology and self-reliance in science and technology.

Wanjie Medical's management team has extensive experience in research and development and commercialization in the orthopedic consumables field. Ms. Zhang Mei, the founder of Wanjie Medical, has over 20 years of deep involvement in the medical device R&D sector, with remarkable insights particularly in sports medicine, orthopedic new materials, and tissue repair, serving as the spiritual pillar for the company’s continuous growth. The core executives of the company all come from well-known domestic medical device enterprises, possessing profound expertise and abundant managerial experience in product development, clinical affairs management, and market expansion.

In the upcoming golden age of medical innovation, Wanjie Medical will continue to focus on the fields of minimally invasive orthopedic surgery and tissue regeneration, striving to provide patients with comprehensive solutions for minimally invasive orthopedic surgical procedures. It aims to promote the substitution of domestically produced medical devices and build a high-quality national brand.

Ms. Zhang Mei, Founder of Wanjie MedicalStated: "Against the backdrop of the current severe challenges in the medical device industry's financing environment, the company has always stayed true to its original mission, firmly implementing an innovation-driven development strategy. We remain focused on in-depth research in tissue repair and minimally invasive orthopedics, continuously launching groundbreaking innovative products. Throughout this process, we are particularly grateful for the long-term support from our existing shareholder, Yilian Capital, and the trust placed in us by our new shareholder, CAS Investment. Looking ahead, our company will continue to rely on its outstanding R&D capabilities and innovative strength, as always, committed to achieving even more brilliant results, creating greater value for shareholders, and contributing more to the development of the industry."

Liu Chunguang, Investment Director of CAS Investment"In the medical field, investment opportunities are evergreen. Under the trend of aging, the incidence of orthopedic diseases such as spinal and joint issues is increasing. With innovative solutions like vertebral body forming and cartilage repair gradually maturing, minimally invasive orthopedic intervention products will experience rapid market growth. Wanjie Medical boasts a diverse product portfolio, covering sports medicine, minimally invasive spine treatment, biomaterials, orthopedic consumables, and more. The company’s team demonstrates foresight and strong innovation capabilities in product development and pipeline layout, offering comprehensive solutions for minimally invasive orthopedic treatments to better meet clinical needs. We are optimistic about Wanjie Medical's future development and will support the company in becoming a leader in the fields of orthopedic minimally invasive treatment and tissue regeneration."

Xu Luobin, Managing Partner of Yilian Capital"We are very pleased to see that Wanjie Medical has successfully completed its financing. As early investors, we have witnessed the company grow from a startup to become a leader in the field of orthopedic minimally invasive and tissue regeneration. The company’s continuous investment in R&D and market expansion has earned widespread recognition. Especially under the current industry challenges, Wanjie Medical has adhered to innovation-driven growth, demonstrating strong resilience and execution capabilities. We believe that after completing this new round of financing, the company will accelerate product development and market layout, providing higher-quality solutions for patients worldwide. Yilian Capital will continue to support Wanjie Medical's development and looks forward to jointly creating an even more brilliant future."

Zhu Peilin, Founding Partner of VCBeat Capital"The orthopedic market in China is experiencing steady growth. As China gradually enters a moderately aging society, the incidence of orthopedic conditions is also on the rise. At the same time, improvements in people's payment capabilities and health awareness are expected to increase the penetration rate of orthopedic surgeries, further driving the growth of the orthopedic market. Wanjie Medical has extensive experience in the research and sales of orthopedic products. The company leads in its key product categories, with a comprehensive layout in tissue regeneration and sports medicine product lines, while also entering the field of minimally invasive spinal surgery. The company’s strong R&D capabilities continue to deliver innovative products like the 'artificial ligament' and 'joint cartilage repair scaffold,' which boast high technological barriers and broad application prospects. We look forward to the company entering a phase of rapid development and will continue to provide support throughout its growth process."

Wanjie Medical is a high-tech enterprise integrating research and development, production, sales, and foreign trade. It has been elected as the vice-chairman unit of the China Sports Medicine Industry-University-Research Innovation Alliance, approved for a postdoctoral research workstation, and awarded multiple honors such as "Specialized, Precise, Unique, and Innovative Little Giant" enterprise in Beijing, Beijing Patent Pilot Unit, and one of the top 20 enterprises in comprehensive R&D strength in China's medical device industry. Wanjie Medical focuses on R&D innovation and aims to become a leading enterprise in the fields of minimally invasive orthopedics (sports medicine and spinal minimally invasive) and tissue regeneration, providing patients with more comprehensive clinical solutions. The company collaborates with well-known expert-led scientific research teams, aggregates professional talents from various fields, and relies on an advanced production system to continuously launch leading medical consumables, equipment, and tools. Adhering to the business philosophy of "fine materials, fine manufacturing, fine products, pursuit of innovation, integrity," it continuously improves its industrial system, enhances R&D capabilities, and optimizes product quality. Wanjie Medical currently owns two innovative medical devices certified by the National Medical Products Administration – "Artificial Ligament" and "Joint Cartilage Repair Scaffold," which will fill the gaps in related fields in China in the future.

CAS Investment is a private equity investment management platform under the Chinese Academy of Sciences, managing funds with a scale exceeding 15 billion RMB. CAS Investment has been ranked on multiple prestigious lists, including the "Top 30 China Venture Capital Institutions of the Year 2024" by Finance China, retaining its position in the "Top 10 China Venture Capital Institutions with the Best Returns (2017-2024)," the "Top 50 China Equity Investment Industry Venture Capital Institutions of 2024" by 36Kr, and named as one of the fund managers with the most consistent top performance in the Greater China region by Preqin. CAS Investment focuses on investing in hard technology fields such as intelligent manufacturing, AI infrastructure, AI applications, and smart healthcare, supporting rapid business growth. Representative investment projects include Siasun Robot, ThunderSoft, Force Technology, Ronbay Technology, Zhuhai CosMX, Ruike Connectivity, ACME, Cambricon, Novosense, Hygon, and BIWIN Storage.

Yilian Capital is an investment firm focused on advanced technology sectors, dedicated to discovering and supporting companies with innovative capabilities and high growth potential. With its deep expertise and extensive industry network, Yilian Capital has played a significant role in driving corporate growth, technological innovation, and market expansion. Yilian Capital's investment portfolio spans multiple fields, including medical devices, biotechnology, integrated circuits, and financial technology, and it has established long-term cooperative relationships with several well-known enterprises and research institutions.

VCBeat Capital is a boutique investment bank focused on the biomedicine field. It was founded by professionals with deep expertise in the healthcare industry and consulting strategy. We are committed to providing services such as financing, licensing, mergers and acquisitions for companies in the biopharmaceuticals, medical devices, and healthcare services sectors. Our business covers China, Europe, the United States, and parts of the Asia-Pacific region. With an in-depth understanding of the industry and meticulous service, VCBeat Capital is becoming a highly favored advisory service provider for companies in the healthcare sector during their financing and external cooperation processes.